WHITNEY REED: Open Payments
NPI 1184091415 · JACKSONVILLE, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$688 in 34 payments from 13 companies in 2025. Trend: 2023 $725 · 2024 $915 · 2025 $688
Food & beverage: $688
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $377 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $61 |
| Paratek Pharmaceuticals, Inc. | 2 | $32 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Lundbeck LLC | 1 | $29 |
| Novo Nordisk Inc | 2 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $24 |
| Abbott Laboratories | 1 | $24 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $20 |
| Smith+Nephew, Inc. | 1 | $16 |
Products named: VRAYLAR, UBRELVY, XIFAXAN, REXULTI, QULIPTA, NUZYRA, CAPLYTA, CARDIOMEMS.
Industry payments across AR — which companies pay providers there.
